Osteoporosis News and Research

Latest Osteoporosis News and Research

Non-pharmacologic interventions for the control of osteoporosis and obesity

The Department of Biomedical Engineering at Stony Brook University received a $1.8 million grant from the National Institutes of Health (NIH) to investigate the biologic and physical mechanisms of very low-magnitude mechanical signals and how they strengthen bone and muscle.

20 Nov 2008

Study identifies causes of bone loss in breast cancer survivors

Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

19 Nov 2008

Computed tomography technology shows anorexia impairs adolescent bone development

Children and teenagers with even mild cases of anorexia exhibit abnormal bone structure, according to a new study appearing in the December issue of Radiology and presented at the annual meeting of the Radiological Society of North America (RSNA).

18 Nov 2008

Breakthrough reveals first ever complete structure of a nuclear hormone receptor on human DNA

For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by Fraydoon Rastinejad, Ph.D., professor of pharmacology and director of the UVA Center for Molecular Design and published in the October 29 issue of Nature, reveals the first ever complete structure of a nuclear hormone receptor on human DNA – a discovery that now clears a new path for scientists to design more effective drugs with fewer associated health risks. “Dr. Rastinejad’s findings fundamentally change the way people all over the world will study how nuclear hormone receptors work and introduces a new platform for designing better drugs,” says Jim Garrison, Ph.D., professor of pharmacology at UVA Health System. Nuclear hormone receptors, including the peroxisome proliferator-activated receptors (PPARs), are proteins that sit on the surface of cells and bind to specific hormones such as estrogen, progesterone and thyroid hormone. Once the receptor binds to its hormone and its DNA regulatory element, it can cause a number of alterations in the cell, switching genes on and off. These switches control the continual regulation of the metabolic system and reproductive tissues, as well as the development and differentiation of skin, bone and behavioral centers in the brain. “PPARs are widely studied because they regulate the genes that produce fat cells, glucose, insulin, lipids and metabolism,” says Dr. Rastinejad. “That’s what makes them such good drug targets for diseases like diabetes. We can design drugs more rationally to bind to the PPAR nuclear receptor complex to help regulate these functions in the body.” A number of diabetes drugs, called insulin sensitizers, have been developed based on that knowledge, but now that scientists have a clear view into how these receptors bind and what shape they take the door is wide open for the development of better drugs. "After 40 years of nuclear receptor research, we finally can view the first full and complete structure of a nuclear receptor, thanks to Dr. Rastinejad’s break-though achievement,” says Bert W. O’Malley, Ph.D., professor and chairman, Department of Molecular and Cellular Biology at Baylor College of Medicine who is widely considered a top expert in the field.

17 Nov 2008

Canadian women unaware of their vitamin D levels

A new survey, conducted by Ipsos Reid, reveals Canadian women are unaware of their vitamin D levels. According to the survey sponsored by Marc Sorenson, Ed.D, 97 per cent of the 516 Canadian women surveyed didn't know their vitamin D levels.

17 Nov 2008

Breast and prostate cancer treatment may result in bone loss

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss.

16 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

Adalimumab therapy may reduce health-care costs for Crohn's disease patients

Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD).

12 Nov 2008

Osteoporosis care at risk in the U.S.

Cuts to Medicare reimbursement of DXA undermine efforts to properly diagnose and treat osteoporosis and diminish quality of patient care.

12 Nov 2008

New research on chronic corticosteroid use

An analysis of large population databases has recently yielded important findings about chronic corticosteroid use.

10 Nov 2008

Scientists on a quest to find the right prescription for exercise

Canadian scientists have a plan in the pipeline to explore just why exercise is so beneficial to the body.

9 Nov 2008

We all know physical activity is good for you. But why exactly is it good for you?

What effect does exercise have on the cells and tissues of the body? What do we need to know so that we can use physical activity more effectively to combat chronic diseases such as arthritis, diabetes and heart disease? And what social and psychological factors prevent people from exercising or playing sports?

8 Nov 2008

Canadian study to look at exercise and physical activity

We all know physical activity is good for you. But why exactly is it good for you? What effect does exercise have on the cells and tissues of the body?

5 Nov 2008

$Healthy bones program reduces hip fractures by 37 percent$

Healthy bones program reduces hip fractures by 37 percent

Proactive measures can reduce hip fracture rates by an average of 37.2 percent -- and as much as 50 percent -- among those at risk, according to a study conducted by Kaiser Permanente Southern California.

5 Nov 2008

$Treating osteoporosis after hip fracture$

Treating osteoporosis after hip fracture

Most patients who suffer a hip fracture are referred to their primary care physicians for osteoporosis follow-up care.

4 Nov 2008

FDA warns Bayer HealthCare on over-the-counter aspirin product

The U.S. Food and Drug Administration today sent Warning Letters to Bayer HealthCare concerning two unlawful, over-the-counter (OTC) aspirin products - Bayer Women's Low Dose Aspirin + Calcium (Bayer Women's) and Bayer Aspirin with Heart Advantage (Bayer Heart Advantage).

28 Oct 2008

Expensive new diabetes drugs don't necessarily produce better outcomes

The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago. The researchers say the findings raise questions about whether the higher cost actually translates into improved care and better outcomes.

28 Oct 2008